ARS Pharmaceuticals (SPRY) Non-Current Debt (2021)

ARS Pharmaceuticals' (SPRY) quarterly Non-Current Debt came in at $4.9 million in Q4 2021.

ARS Pharmaceuticals (SPRY) Non-Current Debt (2021) Analysis & Trends

ARS Pharmaceuticals has disclosed Non-Current Debt across 1 years of filings, most recently posting $4.9 million for Q4 2021.

Non-Current Debt for Q4 2021 came in at $4.9 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $4.9 million (changed N/A YoY), and the FY2021 annual result was $4.9 million, changed N/A from the prior year.
Non-Current Debt came in at $4.9 million for Q4 2021 at ARS Pharmaceuticals.
In the past five years, Non-Current Debt ranged from a high of $4.9 million in Q4 2021 to a low of $4.9 million in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	ARS Pharmaceuticals	954.24 Mn	753.27 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	4.93 Mn
Dec 31, 2021	4.93 Mn